SecBot SecBot
8-K ·Filed Nov 12, 2026

YARW

Yarrow Bioscience, Inc.
NEUTRAL
Impact 4/10
Horizonmonths Processed5d 8h ago SEC0001566044-26-000017
8-K Item 2.02: Earnings release
Actionable Insight • Neutral

No revenue or earnings to evaluate; the stock is a binary event driven by YB-101 Phase 2a data in H2 2027. Monitor enrollment updates and any data readouts from GenSci's Phase 1 MAD trial in TED, also expected H2 2027.

DirectionNeutral
Confidencehigh
Horizonmonths

YB-101

◆ Mixed Named in this 8-K
Impact
Phase
Phase 2a/2b (dosing initiated ~July 27, 2026); Phase 1 SAD in thyroid eye disease previously reported
Time to market
Unknown — mid-stage. If the Phase 2a/2b trial succeeds and later registrational studies follow, approval would be several years away (late 2020s at the earliest); the company currently has no approved products.
Next catalyst
None dated

What to watchYB-101 is a Phase 2a/2b, single-asset bet at a company (Nasdaq: YARW, formerly VYNE) that just closed a reverse merger, raised ~$200M, and began dosing the pivotal-to-next-stage trial, but the defining data readout is not expected until 2H 2027. A non-medical investor should treat YARW as a speculative, liquidity-thin clinical stock: watch for interim Phase 2a/2b data, the exact readout date, and any competitive readouts from anti-FcRn/IgG-degrading drugs in Graves'/thyroid eye disease.

How the stock moved after the report

NEUTRAL VIEWSTOCK BELOW ENTRY AT T+1
Entry
$19.63
T+0 close · Nov 12, 2026 · via day close
Latest settled
−8.15%
T+1 · $18.03
Vs SPY
−7.79%
α at T+1
Next horizon
T+5
tomorrow
  1. T+0 · Nov 12 $19.63entry
  2. T+1 · 4d ago −8.15%α −7.79% · $18.03
  3. T+2 · todayOpen
  4. T+5 · tomorrow Pending
  5. T+20 · in 24d Pending
  6. T+60 · in 3mo Pending

Price Chart

Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Yarrow Bioscience reported Q3 2026 net loss of $9.7M ($0.43 per share) with no revenue, as a pre-revenue clinical-stage biotech. The key event is the ongoing Phase 2a DIRECTION-GD trial for YB-101 in Graves disease, with topline results expected in H2 2027. The company completed a $172.5M public offering in September 2026, extending cash runway into 2030.

Key Financial Metrics

EPS
−$0.43

Key Facts

  • Net loss of $9.7 million for Q3 2026, or $0.43 per share
  • Cash and cash equivalents of $268.9 million as of September 30, 2026
  • Completed approximately $172.5 million underwritten public offering in September 2026
  • Enrollment ongoing in Phase 2a portion of DIRECTION-GD trial for YB-101
  • Phase 2a topline results expected in second half of 2027
  • Cash runway expected to fund operations into 2030
  • 11.5 million common shares and 23.7 million pre-funded warrants outstanding as of September 30, 2026

Financial Impact

Net loss $9.7M; cash position $268.9M post-$172.5M offering

cashnet lossdilution

Risk Factors

  • Pre-revenue clinical-stage biotech with no approved products
  • Phase 2a data for YB-101 not expected until H2 2027, creating binary event risk
  • Significant dilution from 23.7M pre-funded warrants outstanding
  • Prior clinical hold on VYN202 (legacy VYNE asset) highlights regulatory risk

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
89% bullish (9 analysts)

Investment Themes

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001566044-26-000017
Document: yarw-20261112.htm0001566044-26-000017
Document: 0001566044-26-000017-index-headers.html0001566044-26-000017
Document: 0001566044-26-000017-index.html0001566044-26-000017
Document: 0001566044-26-000017.txt0001566044-26-000017
8-K Data (Synthetic)0001566044-26-000017

Track record

13 reports on YARW

Performance horizon

The track record builds as more bullish or bearish reports settle.

Filters
  1. Nov 17, 2026today SC 13G/A Neutral 3/10 Entry $13.93 Now $14.27 +2.44% settles Dec 16
  2. Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $14.20 Now $14.27 +0.49% settles Dec 16
  3. Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $13.93 Now $14.27 +2.44% settles Dec 16
  4. Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $13.93 Now $14.27 +2.44% settles Dec 16
  5. Nov 16, 20261d ago SC 13G/A Neutral 3/10 Entry $15.44 Now $14.27 −7.58% settles Dec 15
  6. Nov 16, 20261d ago SC 13G Neutral 3/10 Entry $18.20 Now $14.27 −21.59% settles Dec 15
  7. Nov 16, 20261d ago SC 13G/A Neutral 3/10 Entry $18.03 Now $14.27 −20.85% settles Dec 15
  8. Nov 13, 20263d ago SC 13G/A Neutral 2/10 Entry $17.35 Now $14.27 −17.75% settles Dec 15
  9. Nov 13, 20263d ago SC 13G Neutral 3/10 Entry $18.03 Now $14.27 −20.85% settles Dec 15
  10. Nov 12, 20265d ago 8-K Neutral 4/10 Viewing Entry $19.63 Now $14.27 −27.31% settles Dec 11
Showing 10 of 13

US Market Status

Market Open · Closes in 22m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 12, 2026